葛兰素史克(GSK.US)超长效IL-5单抗率先在华申报上市

智通财经
01 Jan

智通财经APP获悉,CDE网站显示,葛兰素史克(GSK.US)的德莫奇单抗(depemokimab)在国内申报上市。根据临床试验进展,推测此次申报的适应症为重度嗜酸性粒细胞性哮喘(SEA)。

公开资料显示,德莫奇单抗是GSK开发的新一代抗白介素5(IL-5)单抗,具有更长的半衰期、高结合亲和力和高效力,仅需每半年注射一次。此前,GSK开发的第一代IL-5单抗美泊利珠单抗(商品名:Nucala)为每月1次制剂,已于2015年11月在美国获批上市。据GSK财报,2023年美泊利珠单抗全球销售额约为20亿美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10